Tenascin expression in lichen sclerosus.
In this study, the distribution of tenascin immunoreactivity in 44 cases of vulvar lichen sclerosus (LS) was investigated. To assess the epithelial basement membrane structure, immunostaining with an antibody to type IV collagen was performed. Ten selected cases were also analyzed by in situ hybridization with a tenascin RNA probe to study the cellular distribution of tenascin mRNA synthesis in LS. Strong tenascin immunoreactivity could be found in LS, especially in areas with subepithelial edema and marked inflammation. By in situ hybridization, signals for tenascin mRNA could be found in basal keratinocytes, dermal fibroblasts, and endothelial cells. Staining for type IV collagen often revealed attenuation and discontinuity in the basement membrane. The abnormal accumulation of tenascin in LS suggests that it may participate in the pathogenesis of this disease. As shown by in situ hybridization, the cell types responsible for tenascin synthesis are basal keratinocytes, dermal fibroblasts, and endothelial cells. Because tenascin, together with fibronectin, is able to upregulate the expression of 92 kDa collagenase and stromelysin in fibroblasts, the matrix destruction and basement membrane damage in LS may partly be a consequence of an abnormal accumulation and synthesis of tenascin. The upregulation of tenascin synthesis in dermal fibroblasts, endothelial cells, and keratinocytes in LS could be mediated by an abnormal expression of growth factors, most notably TGF-beta, which are able to stimulate tenascin synthesis in many non-neoplastic and neoplastic cell lines.
Soini
Y
Y
Department of Pathology, University of Oulu, Oulu University Hospital, Finland.
Pöllänen
R
R
Autio-Harmainen
H
H
Lehto
V P
VP
D003094:Collagen / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D018459:Lichen Sclerosus et Atrophicus / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D019063:Tenascin / Q000378:metabolism*; D014844:Vulva / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D014845:Vulvar Diseases / Q000378:metabolism* / Q000473:pathology
D012333:RNA, Messenger; D019063:Tenascin; D003094:Collagen